

handbook of biopharma industry acronyms terms

Handbook of Biopharma Industry Acronyms Terms: Navigating the Language of Biotechnology

handbook of biopharma industry acronyms terms is an essential resource for anyone stepping into the dynamic world of biotechnology and pharmaceuticals. The biopharma industry, known for its rapid innovation and complex scientific processes, is packed with a specialized vocabulary that can feel overwhelming. From clinical trials to regulatory affairs, understanding the common acronyms and terms used daily can accelerate learning, improve communication, and foster collaboration across various teams. Whether you're a newcomer, a seasoned professional, or simply curious about the field, having a reliable guide to the biopharma lexicon is invaluable.

Why a Handbook of Biopharma Industry Acronyms Terms Matters

The biopharmaceutical sector is a melting pot of science, technology, regulatory frameworks, and commercial strategies. Each area comes with its own set of abbreviations and jargon. For instance, terms like "CMC," "GMP," or "IND" might sound cryptic unless you know what they stand for and why they matter. This handbook serves as a bridge to demystify those acronyms, helping stakeholders from researchers to marketers speak the same language.

Moreover, acronyms often vary slightly depending on the context—clinical, manufacturing, regulatory, or business development. Having a comprehensive resource helps avoid confusion and saves time.

Common Acronyms in Biopharma Research and Development

The research and development (R&D) phase is the heart of innovation in biopharma. It's where discoveries transform into potential therapies. Here are some of the key terms you'll encounter:

- ****R&D****: Research and Development — the process of discovering and developing new drugs or therapies.
- ****IND****: Investigational New Drug — an application filed with regulatory authorities (like the FDA in the U.S.) to begin clinical trials.
- ****GLP****: Good Laboratory Practice — standards for laboratory research to ensure quality and integrity.
- ****PK/PD****: Pharmacokinetics/Pharmacodynamics — study of how a drug moves through

and affects the body.

- **CMC**: Chemistry, Manufacturing, and Controls — the detailed information about the drug's composition and manufacturing process, critical for regulatory submissions.

Understanding these acronyms helps in grasping the flow from lab bench to patient bedside.

Decoding Clinical Trial Acronyms: From Phase I to NDA

Clinical trials are the backbone of validating a drug's safety and efficacy. The language here is filled with shorthand that can be puzzling without context.

Phases of Clinical Trials

- **Phase I**: First-in-human trials focusing on safety and dosage.
- **Phase II**: Evaluates efficacy and side effects in a larger group.
- **Phase III**: Confirms effectiveness and monitors adverse reactions in large populations.
- **Phase IV**: Post-marketing studies to gather additional information after approval.

Each phase may be described using acronyms such as **RCT** (Randomized Controlled Trial) or **DBPC** (Double-Blind Placebo-Controlled), which describe the study design ensuring scientific rigor.

Regulatory Submissions and Approvals

- **NDA**: New Drug Application — submitted to regulatory agencies for approval to market a new drug.
- **BLA**: Biologics License Application — similar to NDA but specifically for biologic products.
- **EMA**: European Medicines Agency — the regulatory body overseeing drug approval in the European Union.
- **FDA**: Food and Drug Administration — the U.S. regulatory authority.
- **EUA**: Emergency Use Authorization — temporary authorization for use during public health emergencies.

Recognizing these acronyms can clarify the regulatory landscape and timelines associated with drug development.

Manufacturing and Quality Assurance Acronyms

Manufacturing biologics and pharmaceuticals demands strict adherence to quality and

safety standards. The terminology reflects these rigorous requirements.

Quality and Compliance Terms

- **GMP**: Good Manufacturing Practice — regulations requiring manufacturers to ensure products are consistently produced and controlled.
- **QA**: Quality Assurance — the systematic monitoring of all aspects of production.
- **QC**: Quality Control — testing and inspection to verify product quality.
- **SOP**: Standard Operating Procedure — documented processes to ensure consistency.
- **CAPA**: Corrective and Preventive Action — protocols to fix and prevent issues.

These terms are vital for understanding how products are guaranteed safe before reaching patients.

Business and Commercial Acronyms in Biopharma

Beyond science and manufacturing, the biopharma industry is also a complex business ecosystem full of its own acronyms related to licensing, partnerships, and market strategies.

Key Business Terminology

- **BD**: Business Development — activities related to partnerships, licensing, and expansion.
- **LOI**: Letter of Intent — a preliminary agreement outlining the basic terms of a deal.
- **ROI**: Return on Investment — a measure of profitability.
- **KOL**: Key Opinion Leader — influential experts who can impact drug adoption.
- **CRO**: Contract Research Organization — third-party organizations that conduct research on behalf of sponsors.

Familiarity with these terms helps in understanding how scientific innovation is translated into commercial success.

Tips for Mastering Biopharma Industry Terms

Navigating the sea of acronyms can be daunting, but a few strategies can make the journey smoother.

- **Context is King**: Pay attention to the context in which acronyms appear. The same abbreviation can mean different things in clinical versus manufacturing settings.
- **Create Your Own Glossary**: As you come across new terms, jot them down with definitions. Over time, this personalized handbook becomes a powerful reference.
- **Use Industry Resources**: Many organizations and educational platforms provide up-to-

date glossaries and acronym lists tailored to biopharma.

- ****Engage with the Community****: Discussing terms with colleagues or participating in forums can deepen understanding and reveal nuances.

- ****Stay Updated****: The biopharma field evolves rapidly, and so does its language. Regularly revisiting your handbook ensures you keep pace with new developments.

The Role of Acronyms in Fostering Clear Communication

Clear communication is critical in biopharma, where misinterpretation can lead to costly mistakes or regulatory setbacks. Acronyms, when understood universally, streamline conversations and documentation, making collaboration more efficient. However, overuse or inconsistent use can create barriers.

A well-maintained handbook of biopharma industry acronyms terms acts as a common dictionary, helping cross-functional teams—from scientists and clinicians to regulatory specialists and marketers—stay aligned. It also aids in training new employees and onboarding partners, reducing confusion and accelerating workflow.

Whether you're drafting a regulatory submission, discussing a clinical trial design, or negotiating a licensing agreement, having a solid grasp of biopharma acronyms and terms is indispensable. This handbook serves not just as a list of abbreviations, but as a key to unlocking the language of a fast-paced, innovative industry dedicated to improving health worldwide.

Frequently Asked Questions

What is the 'Handbook of Biopharma Industry Acronyms & Terms' used for?

It is used as a comprehensive reference guide to understand the numerous acronyms and terms commonly used in the biopharmaceutical industry, helping professionals communicate effectively and understand industry-specific language.

Who can benefit from using the Handbook of Biopharma Industry Acronyms & Terms?

Biopharma industry professionals, researchers, regulatory personnel, students, and anyone involved in biopharmaceutical development and commercialization can benefit from this handbook.

Does the handbook include regulatory and clinical trial terminology?

Yes, it typically includes acronyms and terms related to regulatory agencies, clinical trials, drug development processes, manufacturing, and quality control within the biopharma sector.

How often is the Handbook of Biopharma Industry Acronyms & Terms updated?

The handbook is usually updated regularly to reflect new terminology, emerging technologies, and evolving industry standards, though the frequency depends on the publisher or organization maintaining it.

Can the handbook help in understanding global biopharma industry terms?

Yes, many handbooks include internationally recognized terms and acronyms, covering global regulatory bodies and multinational industry standards.

Is the Handbook of Biopharma Industry Acronyms & Terms available in digital format?

Many versions of the handbook are available in both print and digital formats, including PDFs and online databases, to facilitate easy access and searchability.

How does the handbook aid in regulatory submissions?

By providing clear definitions of industry-specific acronyms and terms, the handbook helps ensure accurate communication and compliance in regulatory submissions and documentation.

Are abbreviations for biopharma manufacturing processes included in the handbook?

Yes, the handbook commonly includes acronyms related to manufacturing processes such as GMP (Good Manufacturing Practice), QC (Quality Control), and SOP (Standard Operating Procedure).

Where can one find a reliable Handbook of Biopharma Industry Acronyms & Terms?

Reliable handbooks can be found through industry organizations, professional associations, specialized publishers, or online platforms dedicated to biopharma industry resources.

Additional Resources

Handbook of Biopharma Industry Acronyms Terms: Decoding the Language of Biotechnology and Pharmaceuticals

handbook of biopharma industry acronyms terms serves as an essential resource for professionals, researchers, and stakeholders navigating the intricate landscape of biotechnology and pharmaceutical sectors. The biopharma industry is characterized by its rapid innovation, complex regulatory environment, and specialized scientific terminology. As a result, acronyms and abbreviations have become indispensable tools for efficient communication. However, the sheer volume and diversity of these terms often pose challenges for newcomers and even seasoned experts. This article delves into the critical role of such a handbook, its impact on operational clarity, and the broader implications for industry communication and knowledge management.

The Importance of a Handbook for Biopharma Industry Acronyms and Terms

In an industry where precision and clarity can directly affect research outcomes, regulatory compliance, and patient safety, understanding the specialized language is paramount. The biopharma sector encompasses various domains including drug discovery, clinical trials, manufacturing, regulatory affairs, and commercialization. Each of these domains utilizes a unique set of acronyms that can overlap or differ significantly. For example, terms like IND (Investigational New Drug), GMP (Good Manufacturing Practice), and CRO (Contract Research Organization) are ubiquitous but require contextual understanding.

A comprehensive handbook of biopharma industry acronyms terms consolidates this fragmented terminology into a single reference point. This consolidation enhances communication among cross-functional teams — from scientists and clinical researchers to regulatory professionals and marketing strategists. Moreover, it supports training initiatives and onboarding processes by reducing the learning curve associated with industry jargon.

Bridging Communication Gaps Across Global Teams

Biopharma companies often operate across multiple countries and continents, collaborating with external partners, regulatory bodies, and healthcare providers. Variations in terminology and acronyms across regions can cause misunderstandings, delays, or compliance risks. A standardized handbook acts as a linguistic bridge, harmonizing terminology use and facilitating smoother interactions. For example, regulatory acronyms such as EMA (European Medicines Agency) and FDA (Food and Drug Administration) represent distinct agencies but are frequently referenced in global regulatory strategies.

Key Categories of Biopharma Acronyms and Their Relevance

The biopharma lexicon is vast, but it can be categorized to improve usability and comprehension. The handbook typically organizes acronyms into key functional areas, enabling targeted searches and contextual learning.

Research and Development (R&D)

This category includes acronyms related to drug discovery, preclinical studies, and early-phase clinical research. Examples include:

- **GLP** – Good Laboratory Practice
- **PK** – Pharmacokinetics
- **PD** – Pharmacodynamics
- **QbD** – Quality by Design

Understanding these terms is critical for scientists designing experiments and interpreting data, as well as project managers overseeing timelines and deliverables.

Clinical Development and Trials

Clinical acronyms dominate this sector due to the highly regulated nature of human trials. Typical acronyms include:

- **IRB** – Institutional Review Board
- **GCP** – Good Clinical Practice
- **SAE** – Serious Adverse Event
- **CRF** – Case Report Form

Clinicians, monitors, and regulatory personnel rely on these terms to ensure ethical conduct, data integrity, and patient safety.

Manufacturing and Quality Assurance

Manufacturing processes are tightly regulated, requiring familiarity with standards and practices such as:

- **cGMP** – Current Good Manufacturing Practice
- **QC** – Quality Control
- **QA** – Quality Assurance
- **API** – Active Pharmaceutical Ingredient

These acronyms are crucial for production managers, quality inspectors, and supply chain professionals.

Regulatory Affairs and Compliance

Compliance with global regulations demands fluency in regulatory acronyms, including:

- **NDA** – New Drug Application
- **ANDA** – Abbreviated New Drug Application
- **CTD** – Common Technical Document
- **PMA** – Premarket Approval

Regulatory specialists must interpret and apply these terms accurately to navigate approval pathways.

Challenges in Maintaining an Up-to-Date Acronym Handbook

The dynamic nature of biopharma innovation means that acronyms evolve as new technologies, methodologies, and regulatory frameworks emerge. For instance, the rise of cell and gene therapies has introduced terms such as CAR-T (Chimeric Antigen Receptor T-cell Therapy) and AAV (Adeno-Associated Virus). Digital health applications add layers of complexity with acronyms like RWD (Real-World Data) and AI (Artificial Intelligence).

Maintaining an updated handbook requires continuous monitoring of industry developments and integrating feedback from diverse stakeholders. Furthermore, acronyms can have multiple meanings depending on context, creating potential confusion. For example, “CRO” may refer to Contract Research Organization or Chief Risk Officer, depending on the organizational environment.

Adopting Digital Solutions for Accessibility

To address these challenges, many organizations and industry consortia are developing digital, searchable databases that allow real-time updates and contextual definitions. Interactive platforms can link acronyms to detailed explanations, usage examples, and regulatory references. Such tools improve accessibility and reduce the risk of misinterpretation.

The Strategic Value of Acronym Literacy in Biopharma

Beyond operational clarity, proficiency in biopharma acronyms enhances strategic decision-making. Executives and investors rely on quick comprehension of technical documents, regulatory submissions, and scientific literature to guide portfolio management and resource allocation. Misunderstandings can lead to costly delays or compliance issues.

Moreover, effective communication with external stakeholders—such as healthcare providers, patient advocacy groups, and regulatory agencies—depends on a shared language. A well-curated handbook supports transparency and fosters trust, which are critical in an industry that directly impacts public health.

Training and Onboarding Benefits

Incorporating a handbook of biopharma industry acronyms terms into training programs accelerates knowledge transfer and integration of new hires. For multidisciplinary teams, it ensures that diverse expertise converges on common terminology, enhancing collaboration and innovation.

- Reduces errors caused by misinterpretation
- Improves speed of project execution
- Facilitates compliance with regulatory standards

Conclusion: Navigating Complexity with a Definitive Resource

In an industry as complex and fast-evolving as biopharma, a handbook of biopharma industry acronyms terms is far more than a mere glossary. It is an indispensable tool that underpins effective communication, regulatory compliance, and scientific advancement. By consolidating and standardizing terminology, such a resource empowers professionals to navigate the intricate biopharmaceutical landscape with confidence and precision. As the sector continues to innovate, the ongoing curation and digital transformation of these handbooks will remain critical to sustaining clarity and fostering collaboration across global networks.

[Handbook Of Biopharma Industry Acronyms Terms](#)

Find other PDF articles:

<http://142.93.153.27/archive-th-021/pdf?dataid=Rgm84-8759&title=anne-schraff-lost-and-found.pdf>

handbook of biopharma industry acronyms terms: Handbook of Biopharma Industry Acronyms & Terms Ronald Evens, 2009 The Handbook of BioPharma Industry Acronyms & Terms is a comprehensive reference listing all terms and abbreviations used in the development and marketing of drugs.

handbook of biopharma industry acronyms terms: Handbook of Biopharma Industry Acronyms & Terms Ronald P. Evens, 2008-02-21 .

handbook of biopharma industry acronyms terms: The Ultimate Guide to Pharmaceutical Industry Jargon Pasquale De Marco, 2025-04-09 Embark on a journey through the fascinating world of pharmaceuticals with this comprehensive guide, your ultimate companion to understanding the industry's intricate terminology, scientific concepts, and practices. Delve into the complexities of drug development and clinical trials, unraveling the processes that bring new medicines to market. Explore the intricacies of pharmaceutical manufacturing and quality control, ensuring the safety and efficacy of drugs. Discover the mechanisms of action of different drug classes, gaining insights into how they interact with the body to combat diseases. Master the art of pharmaceutical formulations and dosage forms, understanding how drugs are designed to deliver their therapeutic effects. Navigate the complexities of pharmaceutical packaging and labeling, ensuring patient safety and compliance. Gain insights into the global pharmaceutical supply chain and distribution, exploring the challenges and innovations in delivering medicines to patients worldwide. Uncover the strategies and challenges of pharmaceutical marketing and sales, understanding how drugs are promoted and distributed. Analyze the intricacies of pharmaceutical pricing and reimbursement, examining the factors that influence the cost of medicines. Peer into the future of pharmaceuticals, exploring emerging trends in drug discovery and development, and the promise they hold for addressing global health challenges. With its comprehensive coverage and engaging writing style, this book is an essential resource for students, researchers, healthcare professionals, and anyone seeking a deeper understanding of the pharmaceutical industry. Unlock the mysteries of this ever-evolving field and gain the knowledge you need to navigate the complexities of the pharmaceutical world. If you like this book, write a review!

handbook of biopharma industry acronyms terms: The Combination Products Handbook Susan Neadle, 2023-05-16 Combination products are therapeutic and diagnostic products that combine drugs, devices, and/or biological products. According to the US Food and Drug Administration (FDA), "a combination product is one composed of any combination of a drug and a device; a biological product and a device; a drug and a biological product; or a drug, device and a biological product." Examples include prefilled syringes, pen injectors, autoinjectors, inhalers, transdermal delivery systems, drug-eluting stents, and kits containing drug administration devices co-packaged with drugs and/or biological products. This handbook provides the most up-to-date information on the development of combination products, from the technology involved to successful delivery to market. The authors present important and up-to-the-minute pre- and post-market reviews of international combination product regulations, guidance, considerations, and best practices. This handbook: Brings clarity of understanding for global combination products guidance and regulations Reviews the current state-of-the-art considerations and best practices spanning the combination product lifecycle, pre-market through post-market Reviews medical product classification and assignment issues faced by global regulatory authorities and industry The editor is a recognized international Combination Products and Medical Device expert with over 35 years of industry experience and has an outstanding team of contributors. Endorsed by AAMI - Association for the Advancement of Medical Instrumentation.

handbook of biopharma industry acronyms terms: Legal aspects of outsourcing contracts in the pharmaceutical industry: A practical guide ,

handbook of biopharma industry acronyms terms: Handbook of Computer and Computerized System Validation for the Pharmaceutical Industry Stephen Robert Goldman, 2003 This handbook details methods for sustainable compliance with GxPs and 21 CFR Part 11 validation requirements regarding computerized systems in the pharmaceutical, biotechnology, and medical device industry. The handbook follows FDA guidelines and best industry practices in defining roles, responsib

handbook of biopharma industry acronyms terms: Pharmaceutical Production Bill Bennett, Graham Cole, 2003 This title is a general introduction aimed at all those involved in the engineering stages required for the manufacturr of the active ingredient and its dosage forms.

handbook of biopharma industry acronyms terms: *Study Guide to Accompany Rosdahl & Kowalski's Textbook of Basic Nursing* Lazette Nowicki, Caroline Bunker Rosdahl, Eileen Klein, Mary T. Kowalski, 2002-11-21 This excellent study guide helps LPN/LVN students get the most out of the Textbook of Basic Nursing, Eighth Edition. This concise learning tool allows students to review all the key material from the Eighth Edition and features a self-study CD-ROM they can use to help prepare for class or examinations.

handbook of biopharma industry acronyms terms: National Library of Medicine Current Catalog National Library of Medicine (U.S.),

handbook of biopharma industry acronyms terms: Guide to Cell Therapy GxP Joaquim Vives, Gloria Carmona, 2015-07-24 Guide to Cell Therapy GxP is a practical guide to the implementation of quality assurance systems for the successful performance of all cell-based clinical trials. The book covers all information that needs to be included in investigational medicinal product dossier (IMPD), the launching point for any clinical investigation, and beyond. Guide to Cell Therapy GxP bridges a knowledge gap with the inclusion of examples of design of GLP-compliant preclinical studies; design of bioprocesses for autologous/allogeneic therapies; and instruction on how to implement GLP/GMP standards in centers accredited with other quality assurance standards. Guide to Cell Therapy GxP is an essential resource for scientists and researchers in hospitals, transfusion centers, tissue banks, and other research institutes who may not be familiar with the good scientific practice regulations that were originally designed for product development in corporate environments. This book is also a thorough resource for PhD students, Post-docs, Principal Investigators, Quality Assurance Units, and Government Inspectors who want to learn more about how quality standards are implemented in public institutions developing cell-based products. - Easy

access to important information on current regulations, state-of-the-art techniques, and recent advances otherwise scattered on various funding websites, within conference proceedings, or maintained in local knowledge - Features protocols, techniques for trouble-shooting common problems, and an explanation of the advantages and limitations of a technique in generating conclusive data - Includes practical examples of successful implementation of quality standards

handbook of biopharma industry acronyms terms: Book Review Index - 2009

Cumulation Dana Ferguson, 2009-08 Book Review Index provides quick access to reviews of books, periodicals, books on tape and electronic media representing a wide range of popular, academic and professional interests. The up-to-date coverage, wide scope and inclusion of citations for both newly published and older materials make Book Review Index an exceptionally useful reference tool. More than 600 publications are indexed, including journals and national general interest publications and newspapers. Book Review Index is available in a three-issue subscription covering the current year or as an annual cumulation covering the past year.

handbook of biopharma industry acronyms terms: A Practical Guide to Drug Development in Academia Daria Mochly-Rosen, Kevin Grimes, 2014-07-08 A lot of hard-won knowledge is laid out here in a brief but informative way. Every topic is well referenced, with citations from both the primary literature and relevant resources from the internet. Review from Nature Chemical Biology Written by the founders of the SPARK program at Stanford University, this book is a practical guide designed for professors, students and clinicians at academic research institutions who are interested in learning more about the drug development process and how to help their discoveries become the novel drugs of the future. Often many potentially transformative basic science discoveries are not pursued because they are deemed 'too early' to attract industry interest. There are simple, relatively cost-effective things that academic researchers can do to advance their findings to the point that they can be tested in the clinic or attract more industry interest. Each chapter broadly discusses an important topic in drug development, from preclinical work in assay design through clinical trial design, regulatory issues and marketing assessments. After the practical overview provided here, the reader is encouraged to consult more detailed texts on specific topics of interest. I would actually welcome it if this book's intended audience were broadened even more. Younger scientists starting out in the drug industry would benefit from reading it and getting some early exposure to parts of the process that they'll eventually have to understand. Journalists covering the industry (especially the small startup companies) will find this book a good reality check for many an over-hopeful press release. Even advanced investors who might want to know what really happens in the labs will find information here that might otherwise be difficult to track down in such a concentrated form.

handbook of biopharma industry acronyms terms: The Tech Writer's Survival Guide Janet Van Wicklen, 2009 Presents a comprehensive guide that includes advice on writing, editing and researching, plus a glossary and solutions to common problems encountered on the job.

handbook of biopharma industry acronyms terms: Marketing Information Guide , 1968

handbook of biopharma industry acronyms terms: A Guide to Federal Terms and Acronyms Don Philpott, 2017-12-20 Navigating government documents is a task that requires considerable knowledge of specialized terms and acronyms. This required knowledge nearly amounts to knowing a completely different language. To those who are not fluent, the task can be overwhelming, as federal departments fill their documents with acronyms, abbreviations, and terms that mean little or nothing to the outsider. Would you be able to make sense of a document that described how the COTR reports to the CO regarding compliance with FAR, GPRA, SARA, and FASA? (This is a common procedure in government contracting.) Would you have any clue what was being referred to if you came across MIL-STD-129P? (It is the new standard for Military Shipping Label Requirements.) The sheer number of such terms makes mastering them nearly impossible. But now, these terms and their definitions are within reach. This new edition of A Guide to Federal Terms and Acronyms presents a glossary of key definitions used by the federal government. It is updated to include new acronyms and terminology from various federal government departments. It covers the most

common terms, acronyms, and abbreviations used by each major agency, presenting definitions and explanations in a user-friendly and accessible way. This is an essential tool for anyone who works with federal government information.

handbook of biopharma industry acronyms terms: *Pharmaceutical Sciences* Joseph Price Remington, 1975

handbook of biopharma industry acronyms terms: Abbreviations: The complete guide to abbreviations and acronyms (Collins Word Power) Graham King, 2014-02-28 The complete guide to abbreviations and acronyms.

handbook of biopharma industry acronyms terms: Guide to Reference Material Albert John Walford, 1966

handbook of biopharma industry acronyms terms: Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries Pete Harpum, 2011-09-20 This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly experienced practitioners from within the industry on future directions for drug program management. The book integrates portfolio, program, and project management processes as fundamental for effective and efficient drug product development. Contributing expert authors provide their view of how the projectization approach can be taken forward by the drug industry over the coming years.

handbook of biopharma industry acronyms terms: The Complete Guide to Medical Writing Mark C. Stuart, 2007 'The Complete Guide to Medical Writing' is intended to consider all aspects of medical/scientific writing in one concise introductory text. It explains how to get published, how to write for a particular audience or in a particular media, what the publishing processes are and what the financial rewards might be.

Related to handbook of biopharma industry acronyms terms

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Macacão Nadador Vazado Twill Preto | Handbook Macacão Handbook confeccionado em tecido de viscose sarjada. Sua modelagem evasê, decote V sem alças, abertura lateral, recorte para ajustar a silhueta, bolso faca lateral, pernas

Back to Home: <http://142.93.153.27>